Report Overview

The Global Humanized Mouse Model Market size is expected to be worth around US$ 618.2 Million by 2035 from US$ 278.5 Million in 2025, growing at a CAGR of 8.3% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 47.3% share with a revenue of US$ 131.7 Million

The Global Humanized Mouse Model Market is witnessing significant growth due to the increasing demand for advanced preclinical research tools in drug discovery, immunology, oncology, and infectious disease studies. Humanized mouse models are genetically engineered or engrafted with human cells, tissues, or immune systems, enabling researchers to better replicate human biological responses in laboratory settings. These models have become essential for evaluating drug efficacy, safety, and disease mechanisms before clinical trials.

The market is driven by the rising prevalence of chronic diseases, growing investments in pharmaceutical and biotechnology research, and the increasing adoption of personalized medicine approaches. Humanized mouse models play a crucial role in the development of immunotherapies, cancer treatments, and novel biologics, supporting more accurate and predictive research outcomes.

North America currently dominates the market owing to strong research infrastructure, substantial R&D funding, and the presence of leading pharmaceutical companies. Meanwhile, the Asia-Pacific region is expected to witness rapid growth due to expanding biotechnology sectors and increasing government support for biomedical research. Continuous technological advancements and collaborations between research institutions and industry participants are expected to further accelerate market expansion.

This version is suitable for the introductory section of a market research press release.



Click here for more information: https://market.us/report/humanized-mouse-model-market/


Key Takeaways
In 2025, the Humanized Mouse Model Market was valued at US$ 278.5 Million and is projected to reach US$ 618.2 Million by 2035, expanding at a CAGR of 8.3% during the forecast period.
Based on model type, the market is categorized into Humanized Immune System (HIS) Models, Cell-Line Derived Xenograft (CDX) Models, Genetically Humanized Models (Gene Knock-In/Knock-Out), Humanized Liver Models, and Patient-Derived Xenograft (PDX) Models. Among these, Humanized Immune System (HIS) Models emerged as the leading segment, accounting for 32.8% of the total market share in 2025.
By application, the market is segmented into Oncology, Gene Therapy & Regenerative Medicine, Infectious Diseases, Inflammatory & Autoimmune Diseases, Metabolic Diseases, and Neuroscience. The Oncology segment dominated the market, capturing 44.9% of the overall share.
In terms of species, the market is divided into Mice and Rats. The Mice segment maintained its dominance, representing 86.3% of the market revenue in 2025.
Based on end users, the market includes Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, and Government & Regulatory Bodies. Pharmaceutical & Biotechnology Companies held the largest share, contributing 41.2% of total market revenue.
North America remained the leading regional market, accounting for 47.3% of the global Humanized Mouse Model Market share in 2025.


Key Market Segments
By Model Type
Humanized Immune System (HIS) Models
Cell-Line Derived Xenograft (CDX) Models
Genetically Humanized Models (Gene Knock-In/Knock-Out)
Humanized Liver Models
Patient-Derived Xenograft (PDX) Models
By Application
Oncology
Gene Therapy & Regenerative Medicine
Infectious Diseases
Inflammatory & Autoimmune Diseases
Metabolic Diseases
Neuroscience
By Species
Mice
Rats
By End User
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Government & Regulatory Bodies


Market Key Players
The Jackson Laboratory
Charles River Laboratories
Taconic Biosciences
Horizon Discovery
GenOway
Crown Bioscience
Shanghai Model Organisms Center
Ingenious Targeting Laboratory
Cyagen Biosciences
Pharmaron
Market Dynamics
Driver

The increasing global burden of cancer and other complex diseases is a major driver of the Humanized Mouse Model Market. Humanized mouse models provide researchers with a more accurate representation of human immune responses, making them valuable tools for studying disease mechanisms and evaluating new therapies before clinical trials. According to the World Health Organization (WHO), approximately **20 million new cancer cases and 9.7 million cancer-related deaths** were reported globally in 2022. Furthermore, the International Agency for Research on Cancer (IARC) projects that annual cancer cases could exceed 35 million by 2050**, representing a 77% increase from 2022 levels.

In the United States alone, the National Cancer Institute's SEER Program estimated approximately **2.04 million new cancer cases** and over **618,000 cancer deaths** in 2025. Humanized mouse models are increasingly used in oncology research to assess immunotherapies, targeted therapies, and personalized treatment strategies. As pharmaceutical and biotechnology companies seek more predictive preclinical models to reduce clinical trial failures, demand for advanced humanized mouse platforms continues to expand, supporting market growth worldwide.

Trend

A significant trend shaping the Humanized Mouse Model Market is the rapid expansion of cell and gene therapy development. Humanized mouse models are widely utilized to evaluate therapeutic efficacy, immune responses, biodistribution, and safety profiles of innovative treatments before human testing. The U.S. Food and Drug Administration (FDA) reports a steadily growing pipeline of cellular and gene therapy products, reflecting strong innovation across oncology, rare diseases, and regenerative medicine.

Recent regulatory approvals further demonstrate this momentum. For example, the FDA approved novel gene therapies such as treatments for rare immune disorders and genetic skin diseases, highlighting the increasing clinical translation of advanced therapies. Humanized mouse models play a crucial role in these programs because they can mimic human immune system interactions that traditional animal models cannot fully reproduce.

Additionally, advances in gene-editing technologies such as CRISPR have improved the creation of sophisticated humanized models with enhanced biological relevance. As precision medicine initiatives continue to expand globally and more cell and gene therapy candidates enter development pipelines, the use of humanized mouse models is expected to become increasingly integrated into preclinical research workflows across pharmaceutical, biotechnology, and academic institutions.

Restraint

Despite their scientific advantages, the Humanized Mouse Model Market faces restraints related to high development costs, technical complexity, and ethical concerns. Creating a humanized mouse model requires specialized breeding facilities, genetically modified strains, human tissue or stem cell engraftment, and highly trained personnel. These requirements substantially increase research costs compared with conventional laboratory animal models.

Moreover, humanized models often involve lengthy development timelines and variable engraftment success rates, which can affect reproducibility and study outcomes. Regulatory oversight surrounding animal research has also become increasingly stringent across major research regions. Government agencies and institutional review boards require strict compliance with animal welfare regulations, adding administrative and operational burdens for research organizations.

Another challenge is that humanized mouse models, while more predictive than traditional models, still cannot fully replicate the complexity of human physiology. As a result, some therapies that show promise in preclinical studies may not achieve the same outcomes in human clinical trials. The growing emphasis on the “3Rs” principle—Replacement, Reduction, and Refinement of animal use in research—also encourages researchers to explore alternative methods such as organoids, organ-on-chip systems, and computational modeling, which may limit market expansion in certain applications.

Opportunity

The growing focus on precision medicine and immunotherapy presents a substantial opportunity for the Humanized Mouse Model Market. These models enable researchers to study human-specific immune responses and evaluate patient-targeted treatments in a controlled environment, making them highly valuable for next-generation drug development.

According to WHO data, nearly 1 in 5 people worldwide are expected to develop cancer during their lifetime, underscoring the urgent need for more effective and personalized treatment approaches. Additionally, more than 53 million people worldwide were living within five years of a cancer diagnosis in 2022, highlighting the expanding population that could benefit from innovative therapies.

Patient-derived xenograft humanized models are gaining attention because they allow researchers to test therapies using actual patient tumor samples, supporting individualized treatment strategies. Growing government investments in biomedical research, cancer programs, and rare disease initiatives are further strengthening opportunities for advanced preclinical platforms. In India, cancer cases surpassed 1.53 million new diagnoses in 2024, reflecting increasing demand for innovative oncology research tools. As personalized medicine, immuno-oncology, and regenerative medicine continue to evolve, the need for highly predictive humanized mouse models is expected to rise significantly across global research ecosystems.

Conclusion

The global Humanized Mouse Model Market is poised for substantial growth, driven by increasing demand for advanced preclinical research tools, expanding oncology and immunotherapy studies, and rising investments in pharmaceutical and biotechnology research. Humanized mouse models have become essential for improving the predictability of drug development processes by providing more accurate representations of human biological responses. The growing adoption of precision medicine, cell and gene therapies, and personalized treatment approaches is further accelerating market expansion. With a projected market value of US$ 618.2 Million by 2035, up from US$ 278.5 Million in 2025, the industry is expected to maintain strong momentum at a CAGR of 8.3%. North America's leadership, supported by robust research infrastructure and significant R&D investments, continues to shape global market dynamics. Meanwhile, emerging opportunities across Asia-Pacific and other developing regions are expected to contribute to future growth. As technological advancements enhance the development and application of humanized models, the market is likely to play an increasingly important role in advancing drug discovery, translational research, and next-generation therapeutic innovations worldwide.